Advertisement

Topics

Takeda Refocuses Research & Development On Targeted Therapeutic Areas, Concentrating in Japan and the U.S.

07:41 EDT 30 Jul 2016 | Takeda

Osaka, Japan, July 29, 2016 --- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced plans to accelerate the research & development (R&D) organization transformation by refocusing on three key therapeutic areas – Oncology, Gastroenterology (GI) and Central Nervous System (

Original Article: Takeda Refocuses Research & Development On Targeted Therapeutic Areas, Concentrating in Japan and the U.S.

NEXT ARTICLE

More From BioPortfolio on "Takeda Refocuses Research & Development On Targeted Therapeutic Areas, Concentrating in Japan and the U.S."

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...